Welcome to our dedicated page for Celanese SEC filings (Ticker: CE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Celanese's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Celanese's regulatory disclosures and financial reporting.
Celanese Corp’s CEO and President, who also serves as a director, increased his personal stake in the company through a recent stock purchase. On 12/10/2025, he acquired 3,800 shares of Celanese common stock in an open market transaction coded as a purchase at a price of $41.5899 per share. Following this transaction, he beneficially owned 70,448.703 shares directly and an additional 597.0315 shares indirectly through a 401(k) plan. The form was filed for one reporting person, reflecting continued alignment of the senior executive’s holdings with Celanese’s equity.
Celanese Corp insider Chuck Kyrish, the company’s SVP & CFO, reported an equity transaction involving 5,000 shares of Celanese common stock on December 9, 2025, at a weighted average price of about $41.03 per share. After this activity, he beneficially owned 10,914.476 shares directly. The filing notes that the shares were executed in multiple trades within a price range from $40.885 to $41.112, and that detailed trade-by-trade information is available from the reporting person upon request.
Celanese Corporation announced that its subsidiary Celanese US Holdings LLC entered into an underwriting agreement for a new senior notes offering. The Issuer agreed to sell $600,000,000 aggregate principal amount of 7.000% Senior Notes due 2031 and $800,000,000 aggregate principal amount of 7.375% Senior Notes due 2034. The transaction is being conducted through a registered public offering under an existing shelf registration statement on Form S-3, using a prospectus, a related prospectus supplement dated December 2, 2025, and a free writing prospectus filed on December 3, 2025.
Celanese Corporation announced that its wholly owned subsidiary Celanese US Holdings LLC has launched cash tender offers to buy back up to an aggregate principal amount of $1,000,000,000 of its outstanding senior notes. The offers target its 6.665% Senior Notes due 2027 and 6.850% Senior Notes due 2028.
The 2028 notes are subject to a series cap, limiting purchases of that issue to a maximum aggregate principal amount of $100,000,000. The tender offers are being made on the terms and conditions described in an Offer to Purchase dated December 2, 2025, and represent a step in managing the company’s outstanding debt profile and interest-bearing obligations.
Celanese Corp (CE) reported an equity award to Chief Accounting Officer Aaron M. McGilvray. On 11/17/2025, he acquired 2,980 time-based restricted stock units (RSUs) of Celanese common stock at a price of $0 as a compensatory grant. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
The RSUs will vest, subject to continued employment, in two equal installments of 50% on November 17, 2026 and November 17, 2027. Following this grant, McGilvray beneficially owns 10,319.378 shares directly and 798.8018 shares indirectly through a 401(k) plan.
Celanese Corp (CE) reported an equity award to a senior executive. A Form 4 filing shows that an officer serving as SVP & General Counsel received 6,624 shares of Celanese common stock on 11/17/2025 in the form of time-based restricted stock units granted under the company’s Amended and Restated 2018 Global Incentive Plan. The award was recorded at a price of $0 per share, reflecting that it is a compensatory grant rather than an open-market purchase.
Each RSU represents the right to receive one share of common stock, with vesting subject to continued employment. The RSUs will vest 50% on November 17, 2026 and the remaining 50% on November 17, 2027. After this grant, the reporting person directly beneficially owned 20,459 shares, and an additional 624.623 shares were held indirectly through a 401(k) plan.
Celanese Corp (CE) director Kim K.W. Rucker filed a Form 4 reporting the acquisition of 7.29 shares of phantom stock on 11/12/2025, coded “A.” The filing lists a price of $39.12 for the derivative security.
Each phantom share represents the right to receive one share of common stock, with payment in stock under the company’s 2008 Deferred Compensation Plan after the director’s service ends. Following the transaction, 9,514.09 derivative securities were beneficially owned directly.
Celanese Corp (CE) director Deborah J. Kissire reported an acquisition of derivative securities on a Form 4. On 11/12/2025, she acquired 4.54 units of phantom stock (Transaction Code A) at a price of $39.12 per the derivative security entry.
Each phantom stock unit represents the right to receive one share of Common Stock. Following the transaction, she beneficially owned 5,921.288 derivative securities directly. The phantom stock relates to dividend equivalents under the company’s 2008 Deferred Compensation Plan and becomes payable in shares after her service as a director ends.
Celanese (CE) director Jay V. Ihlenfeld filed a Form 4 reporting an acquisition of 7.84 shares of phantom stock on 11/12/2025 (Code A). Following this transaction, he beneficially owns 10,235.059 derivative securities, held directly.
Each phantom share represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan and becomes payable in common shares after the director’s service ends, as provided in the plan.
Celanese Corp (CE) reported a Form 4 for director Kathryn Hill. On 11/12/2025, she acquired 2.26 units of phantom stock (transaction code A) at a derivative price of $39.12. After this transaction, she beneficially owned 2,948.87 derivative securities directly.
Each phantom stock unit represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan and becomes payable in shares of common stock following the end of her service as a director.